Refractory Leukemia: Clinical Trials

2 trials for Refractory Leukemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed. 2 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 22Completed 2
Phase 11Completed 1

Follow Refractory Leukemia: new trials by email Literature Review of Refractory Leukemia trials Research Report on Refractory Leukemia

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm
CD123 targeted CAR-NK cells - Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Phase 1 / Phase 2CompletedChongqing Precision Biotech Co., Ltd52024-03-282026-08-05
Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)
Panobinostat/LBH589 - Refractory Leukemia, Acute Myelogenous Leukemia
Phase 2CompletedNovartis Pharmaceuticals592009-08-012017-02-23

Narrower conditions

Leukemia (2)  ·  Leukemia, Myeloid, Acute (2)  ·  Blastic Plasmacytoid Dendritic Cell Neoplasm (1)

Broader conditions

Hematologic Diseases (2)  ·  Hemic and Lymphatic Diseases (2)  ·  Leukemia, Myeloid (2)  ·  Neoplasms (2)  ·  Neoplasms by Histologic Type (2)  ·  Hematologic Neoplasms (1)  ·  Histiocytic Disorders, Malignant (1)  ·  Lymphoma (1)  ·  Neoplasms by Site (1)  ·  Skin Diseases (1)  ·  Skin Neoplasms (1)  ·  Skin and Connective Tissue Diseases (1)

Interventions

Panobinostat (1)

Sponsors

Chongqing Precision Biotech Co., Ltd (1)  ·  Novartis Pharmaceuticals (1)

Countries

Australia (1)  ·  Belgium (1)  ·  China (1)  ·  France (1)  ·  Germany (1)  ·  Italy (1)  ·  Peru (1)  ·  South Korea (1)  ·  Spain (1)  ·  Switzerland (1)  ·  Turkey (Türkiye) (1)  ·  United Kingdom (1)  ·  United States (1)

Top investigators

Jia Wei, M.D (1)

NIH funding

2008 (1)